Agilent

The test is now CE marked for use in identifying patients with urothelial cancer who are most likely to benefit from Opdivo therapy.

The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio. 

The companies will work together to develop a next-generation sequencing-based kit version of Agendia's molecular breast cancer diagnostics.

The test can now be used to identify patients with squamous cell carcinoma of the head and neck who are likely to benefit from Opdivo therapy.

The European Commission has now approved the anti-PD-1 therapy Keytruda, and the Dako test with it, as a first-line treatment for non-small cell lung cancer.

The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.

The collaborators will explore the use of cell-free DNA for preimplantation genetic testing. 

ASI's CEO said the clearance gives labs a system that eliminates the need for costly internal validation.